Pay in 4 interest-free payments of $7.33 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
In Phase 3 trials, it demonstrated substantial weight loss and improved glycemic control in patients with type 2 diabetes
Mol Nutr Food Res 65:e2100214
Neuropsychopharmacology, 46, 1263-1271
Through their mechanism of action, they may contribute to metabolic optimization, aiding individuals focused on structured weight loss and maintenance strategies
The cardiac benefits of GLP-1 agonists were not anticipated before outcome studies were performed for several reasons: (1) Historical Precedent-past experiences with other diabetes medications that unexpectedly had adverse cardiovascular effects made it less likely for researchers and clinicians to anticipate potential cardiovascular benefits without concrete evidence from large-scale trials
:max_bytes(150000):strip_icc()/VWH-GettyImages-2126120259-c2442d334436484baa255439265b7fb1.jpg)
